• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?

    5/10/24 12:45:52 PM ET
    $ANET
    $CHTR
    $CMRE
    $DOCN
    Computer Communications Equipment
    Telecommunications
    Cable & Other Pay Television Services
    Telecommunications
    Get the next $ANET alert in real time by email

    A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.

    The report disclosed that both near-term and long-term inflation expectations have surged beyond projections this month, causing the broader consumer gauge to hit its lowest levels in six months.

    “If spending slows down and inflation increases, we'll get the opposite of the Goldilocks scenario that many were hoping for, and the Fed will be in an especially difficult position of choosing between accommodating a slowing economy and fighting increasing inflation expectations,” said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.

    Echoing this view, Jeffrey Roach, chief economist for LPL Financial, sees rising risks of stagflation, a concern that could unsettle markets.

    At 12:05 p.m. trading in New York, the S&P 500 was 0.1% lower, but it was firmly up by 1.6% for the week, poised to secure a third consecutive week of gains after three of losses.

    The Dow Jones Industrial Average was a tad higher, battling to secure the eight straight session of gains, the longest positive streak since December 2023. Tech stocks were flat. Small caps were the underperformers, with the iShares Russell 2000 ETF (NYSE:IWM) down 0.9%.

    The rising inflation perceptions in the consumer survey rescued the dollar, which eyes a positive weekly close, after two negative ones.

    Treasury yields also inched higher by about 4 basis points across all maturities. The 10-year benchmark hit 4.50%.

    Gold surged to $2,385/oz, with the SPDR Gold Trust (NYSE:GLD) up 0.8%.

    The dismal consumer sentiment data sharply weighed on Bitcoin (CRYPTO: BTC) with the largest cryptocurrency dropping over 4% from $63,000 to below $60,500 following the report.

    Chart of The Day: Michigan Consumer Sentiment Knocked On Bitcoin

    Friday’s Performance In Major US Indices, ETFs

    Major IndicesPrice1-day %chg
    Dow Jones39,411.320.1 %
    Nasdaq 10018,108.220.0%
    S&P 5005,209.09-0.1 %
    Russell 2000204.04-0.9%
    Updated at 1:05 p.m.

    The SPDR S&P 500 ETF Trust (NYSE:SPY) was unchanged at $520.20, the SPDR Dow Jones Industrial Average (NYSE:DIA) rose 0.2% to $394.65 and the tech-heavy Invesco QQQ Trust (NASDAQ:QQQ) was up 0.1% to $441.38, according to Benzinga Pro data. 

    Sector-wise, the Financials Select Sector SPDR Fund (NYSE:XLF) outperformed, up 0.5%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:XLY) was the major laggard, down 0.6%.

    Friday’s Stock Movers

    • Novavax Inc. (NASDAQ:NVAX) surged by an astonishing 122%, after the company announced a Covid-19 vaccine licensing deal with Sanofi (NASDAQ:SNY). The pharmaceutical company reported a lower than expected loss last quarter, but missed revenue estimates.
    • MacroGenics Inc. (NASDAQ:MGNX) tumbled by 77% following an interim update on a mid-stage study of a cancer drug candidate, which reported the unfortunate deaths of several study participants. Furthermore, the results for the quarter fell short of expectations.
    • Charter Communications Inc. (NASDAQ:CHTR) rose 0.6% after the company started a tender offer to buy back senior secured notes due 2025 for up to $1.7 billion in cash.
    • Moderna Inc. (NASDAQ:MRNA) dropped by 4% after the company announced that the FDA won’t finish its review of MRNA’s respiratory syncytial virus (RSV) vaccine by the scheduled action date of May 12 due to administrative constraints. The FDA has communicated that it anticipates completing the review by the end of May.
    • Companies reacting to earnings were Gen Digital Inc. (NASDAQ:GEN) up 15%, Mettler-Toledo International Inc. (NYSE:MTD) up 14%, Akamai Technologies Inc. (NYSE:ANET) down 10%, Ubiquiti Inc. (NYSE:UI) up 8%, DigitalOcean Holdings Inc. (NYSE:DOCN) up 6.6%, Construction Partners Inc. (NASDAQ:ROAD) up 2.6%, Sylvamo Corp. (NYSE:SLVM) down 5%, Costamare Inc. (NYSE:CMRE) up 1.3%, Marathon Digital Holdings Inc. (NASDAQ:MARA) down 8%, Insulet Corp. (NASDAQ:PODD) down 4%, H&R Block Inc. (NYSE:HRB) up 9.7%, and Genpact Ltd. (NYSE:G) up 5.7%.

    Read now: Tesla German Gigafactory Faces Climate Protestors Friday: ‘Why Are They Not Jailed,’ Musk Asks

    Image generated using artificial intelligence via Midjourney.

    Get the next $ANET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANET
    $CHTR
    $CMRE
    $DOCN

    CompanyDatePrice TargetRatingAnalyst
    Sanofi
    $SNY
    2/12/2026Buy → Neutral
    BofA Securities
    MARA Holdings Inc.
    $MARA
    2/9/2026$8.00Underweight
    Morgan Stanley
    DigitalOcean Holdings Inc.
    $DOCN
    2/5/2026$68.00Neutral → Overweight
    Cantor Fitzgerald
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Sanofi
    $SNY
    1/27/2026Neutral
    Citigroup
    Insulet Corporation
    $PODD
    1/27/2026$294.00Hold
    TD Cowen
    Construction Partners Inc.
    $ROAD
    1/16/2026$117.00Neutral
    B. Riley Securities
    Sanofi
    $SNY
    1/16/2026Buy → Neutral
    UBS
    More analyst ratings

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi downgraded by BofA Securities

    BofA Securities downgraded Sanofi from Buy to Neutral

    2/12/26 7:23:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on MARA Holdings Inc. with a new price target

    Morgan Stanley initiated coverage of MARA Holdings Inc. with a rating of Underweight and set a new price target of $8.00

    2/9/26 7:01:42 AM ET
    $MARA
    EDP Services
    Technology

    DigitalOcean upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded DigitalOcean from Neutral to Overweight and set a new price target of $68.00

    2/5/26 6:50:53 AM ET
    $DOCN
    Computer Software: Programming Data Processing
    Technology

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARA Schedules Conference Call for Fourth Quarter and Fiscal Year 2025 Financial Results

    Earnings Webcast and Conference Call Set for Thursday, February 26, 2026 at 5:00 p.m. ET Miami, FL, Feb. 20, 2026 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a leading digital energy and infrastructure company, will hold a webcast and conference call on Thursday, February 26, 2026 at 5:00 p.m. Eastern time to discuss its financial results for the quarter and fiscal year ended December 31, 2025. Financial results will be published in a shareholder letter prior to the call on the investor relations section of the Company's website. To register to participate in the conference call or to listen to the live audio webcast, please use this link. The webcas

    2/20/26 8:05:00 AM ET
    $MARA
    EDP Services
    Technology

    DigitalOcean Elevates its Agentic Inference Cloud with GPU Droplets powered by AMD Instinct™ MI350X GPUs

    DigitalOcean and AMD collaborate to deliver new GPUs with lower latency and higher throughput for complex inference workloads DigitalOcean (NYSE:DOCN), the Agentic Inference Cloud built for production AI at scale, today announced the availability of new, high-performance GPU Droplets powered by AMD Instinct™ MI350X GPUs. By integrating these GPUs into its Agentic Inference Cloud, DigitalOcean continues to deliver cost-efficient, high-performance solutions for leading AI-native companies like ACE Studio to scale their inference workloads. Next quarter, DigitalOcean will also deploy AMD Instinct™ MI355X GPUs, marking the addition of liquid-cooled racks to their offering and further expandin

    2/19/26 9:00:00 AM ET
    $DOCN
    Computer Software: Programming Data Processing
    Technology

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANET
    $CHTR
    $CMRE
    $DOCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Nowaid Zabi was granted 197,919 shares, increasing direct ownership by 22% to 1,092,552 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/20/26 9:56:02 PM ET
    $MARA
    EDP Services
    Technology

    Chief Executive Officer Thiel Frederick G was granted 752,093 shares, increasing direct ownership by 18% to 4,907,815 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/20/26 9:56:08 PM ET
    $MARA
    EDP Services
    Technology

    Chief Financial Officer Khan Salman Hassan was granted 494,798 shares, increasing direct ownership by 32% to 2,028,997 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/20/26 9:55:59 PM ET
    $MARA
    EDP Services
    Technology

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Chrystal John C bought $135,693 worth of shares (5,000 units at $27.14), increasing direct ownership by 21% to 28,419 units (SEC Form 4)

    4 - Gen Digital Inc. (0000849399) (Issuer)

    11/14/25 5:16:56 PM ET
    $GEN
    Computer Software: Prepackaged Software
    Technology

    Director Heiden William K bought $150,515 worth of shares (100,000 units at $1.51), increasing direct ownership by 909% to 111,000 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    8/21/25 4:19:48 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $CHTR
    $CMRE
    $DOCN
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Sylvamo Corporation

    10-K - Sylvamo Corp (0001856485) (Filer)

    2/20/26 1:35:02 PM ET
    $SLVM
    Paper
    Basic Materials

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gen Launches Agent Trust Hub for Safer Agentic Era

    Following viral introduction of OpenClaw, data reveals more than 18,000 instances open for attack MOUNTAIN VIEW, Calif., Feb. 4, 2026 /PRNewswire/ -- Gen (NASDAQ:GEN), a global leader powering Digital Freedom with a family of trusted brands including Norton, Avast, LifeLock, MoneyLion and more, today announced the launch of the Gen Agent Trust Hub, a new security platform designed for safer autonomous AI agent adoption. Gen is squarely positioned to provide the trust layer in the AI Agentic Era.  Autonomous agents – AI that can read emails, manage financial workflows, and act

    2/4/26 9:00:00 AM ET
    $GEN
    Computer Software: Prepackaged Software
    Technology

    H&R Block Enhances Board Expertise with New Appointments

    KANSAS CITY, Mo., Jan. 22, 2026 (GLOBE NEWSWIRE) -- H&R Block (NYSE:HRB), a leading global consumer tax services provider, today announced the appointment of three new members to its Board of Directors: Geralyn Breig, former President of Revlon North America; Christian Charnaux, Chief Development Officer of Hilton Worldwide Holdings, Inc.; and Stephanie Plaines, former CFO of JCPenney. "Maintaining a strong, diverse board remains a top priority, and these appointments advance our ongoing goals of broadening expertise, adding fresh perspectives, and strengthening board succession planning while returning it to a more optimal size," said Richard Johnson, H&R Block Chairman of the Board. "Th

    1/22/26 4:51:13 PM ET
    $HRB
    Other Consumer Services
    Consumer Discretionary

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Financials

    Live finance-specific insights

    View All

    MARA Schedules Conference Call for Fourth Quarter and Fiscal Year 2025 Financial Results

    Earnings Webcast and Conference Call Set for Thursday, February 26, 2026 at 5:00 p.m. ET Miami, FL, Feb. 20, 2026 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a leading digital energy and infrastructure company, will hold a webcast and conference call on Thursday, February 26, 2026 at 5:00 p.m. Eastern time to discuss its financial results for the quarter and fiscal year ended December 31, 2025. Financial results will be published in a shareholder letter prior to the call on the investor relations section of the Company's website. To register to participate in the conference call or to listen to the live audio webcast, please use this link. The webcas

    2/20/26 8:05:00 AM ET
    $MARA
    EDP Services
    Technology

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Insulet Reports Fourth Quarter and Full Year 2025 Results

    Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company's guidance range of 25% to 28% in constant currency Total Omnipod

    2/18/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $ANET
    $CHTR
    $CMRE
    $DOCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MARA Holdings Inc.

    SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)

    11/14/24 6:13:30 PM ET
    $MARA
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care